<!--#if expr="$title" --> <!--#echo var="title" --> <!--#else --> HIV Drug Resistance Database <!--#endif -->
Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

MARVEL on RT mutations at position 151


HIVdb Algorithm: Comments & Scores
  • Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with mutations at the associated positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate-level resistance to TDF, 3TC and FTC.
  • Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with mutations at the associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate-level resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M.

Mutation3TCFTCABCAZTD4TDDITDF 184I606015-10-1010-10 184V606015-10-1010-10 41L551015151010 67N005151555 67E005101055 67G005101055 67STH005101055 70R001030151010 210W551015151010 215Y551545451515 215F551545451515 219QENRW005101055 40F5555555 44DA0000000 118I0000000 215CDEIVS00102020105 215NAL00102020105 65R303045-15456060 65N151525-10252525 65E00100101010 70GE101015-10151515 70TSNQ1010100101010 74I003000600 74V003000600 115F004500015 62V5555555 75I5555555 77L55101010105 116Y55101010105 151L10103030303010 151M15156060606015 66i30304545454545 67i30304545454545 68i30304545454545 69i30304545454545 70i30304545454545 71i30304545454545 66d15153030303030 67d15153030303030 68d15153030303030 69d1515150151515 70d1515150151515 71d1515150151515 69D000010300 69N00055100 69G0010010105 75M0001040150 75T0010060300 75S000010100 75A000010100 75L000010100 348I000101000
Footnote:Mutation scores on the left are derived from published literature linking mutations and ARVs (the complete details can be found in the HIVdb Release Notes).
Genotype-treatment correlation
Mutation frequency according to subtype and drug-class experience.
The frequency of each mutation at position 151 according to subtype and drug-class experience. Data are shown for the 8 most common subtypes. The number of persons in each subtype/treatment category is shown beneath the subtype. Mutations occurring at a frequency >0.5% are shown. Each mutation is also a hyper-link to a separate web page with information on each isolate, including literature references with PubMed abstracts, the GenBank accession number, and complete sequence and treatment records.

PosWTRTI Naive Persons NRTI (but no NNRTI) Treated Persons
A
3444
B
23322
C
8513
D
1288
F
695
G
1370
AE
5379
AG
2725
 
A
175
B
4120
C
451
D
126
F
82
G
145
AE
333
AG
76
151 Q          M 1.2 M 1.6 M 1.4 M 0.8  M 0.7 M 2.8  
Footnote: The query page Mutation Prevalence According to Subtype and Treatment to examine the frequency of all mutations according to subtype and treatment; The program HIVSeq provides similar output for mutations in user-submitted sequences; A complete description of the program that generates these tables can be found at Rhee et al AIDS 2006.
 

Mutation frequency according to treatment with individual ARVs.
The first row shows the frequency of the mutation in persons who are RTI-naive (indicated in green). The second row shows the frequency of the mutation in persons who have received one or more NRTIs (+/- NNRTIs). The following rows show the frequency of the mutation in persons who have received only a single NRTI. Mutation rates that differ significantly between treated and untreated isolates are indicated in yellow.
MutationNRTINNRTINumSeqNumMut% Mutantp
Q151H004862050.00 
Q151H>=1>=01977250.000.262
Q151HAZT>=04530  
Q151HDDI>=0530  
Q151HD4T>=0550  
Q151HABC>=0460  
Q151HD4T+3TC>=0298120.000.076
Q151HAZT+3TC>=021240  
Q151HD4T+DDI>=04620  
Q151HAZT+DDI>=05130  
Q151HABC+3TC>=023010.400.005
Q151HTDF+3TC>=02840  
Q151HTDF+FTC>=01500  
MutationNRTINNRTINumSeqNumMut% Mutantp
Q151K004862080.00 
Q151K>=1>=01977230.000.832
Q151KAZT>=04530  
Q151KDDI>=0530  
Q151KD4T>=0550  
Q151KABC>=0460  
Q151KD4T+3TC>=0298150.100.000
Q151KAZT+3TC>=0212410.000.838
Q151KD4T+DDI>=046220.400.000
Q151KAZT+DDI>=05130  
Q151KABC+3TC>=02300  
Q151KTDF+3TC>=02840  
Q151KTDF+FTC>=01500  
MutationNRTINNRTINumSeqNumMut% Mutantp
Q151L004862010.00 
Q151L>=1>=019772120.000.000
Q151LAZT>=04530  
Q151LDDI>=0530  
Q151LD4T>=0550  
Q151LABC>=0460  
Q151LD4T+3TC>=0298150.100.000
Q151LAZT+3TC>=0212410.000.142
Q151LD4T+DDI>=046230.600.000
Q151LAZT+DDI>=05130  
Q151LABC+3TC>=02300  
Q151LTDF+3TC>=02840  
Q151LTDF+FTC>=01500  
MutationNRTINNRTINumSeqNumMut% Mutantp
Q151M00486200  
Q151M>=1>=0197725742.900.000
Q151MAZT>=04530  
Q151MDDI>=0530  
Q151MD4T>=05511.800.000
Q151MABC>=0460  
Q151MD4T+3TC>=029811103.600.000
Q151MAZT+3TC>=0212460.200.000
Q151MD4T+DDI>=0462265.600.000
Q151MAZT+DDI>=0513163.100.000
Q151MABC+3TC>=023010.400.000
Q151MTDF+3TC>=028431.000.000
Q151MTDF+FTC>=01500  
MutationNRTINNRTINumSeqNumMut% Mutantp
Q151P004862090.00 
Q151P>=1>=01977240.000.874
Q151PAZT>=04530  
Q151PDDI>=0530  
Q151PD4T>=0550  
Q151PABC>=0460  
Q151PD4T+3TC>=029810  
Q151PAZT+3TC>=0212410.000.896
Q151PD4T+DDI>=04620  
Q151PAZT+DDI>=051310.100.218
Q151PABC+3TC>=02300  
Q151PTDF+3TC>=02840  
Q151PTDF+FTC>=01500  
MutationNRTINNRTINumSeqNumMut% Mutantp
Q151R0048620180.00 
Q151R>=1>=01977290.000.768
Q151RAZT>=04530  
Q151RDDI>=0530  
Q151RD4T>=0550  
Q151RABC>=0460  
Q151RD4T+3TC>=029810  
Q151RAZT+3TC>=021240  
Q151RD4T+DDI>=04620  
Q151RAZT+DDI>=05130  
Q151RABC+3TC>=02300  
Q151RTDF+3TC>=02840  
Q151RTDF+FTC>=01500  
Footnote: About one-half of the untreated isolates belong to non-subtype B isolates; About 20% of the treated isolates belong to non-subtype B isolates; A page containing summaries for all of the mutations at this position can be found here.

Genotype-phenotype correlation
Phenotypes of top 10 common patterns of drug resistance mutations with mutations at position 151.
Mutation patterns are listed in the frequency with which they have been reported in the published literature. The median level of fold resistance (compared with wildtype) for viruses with the mutation pattern in the first column are indicated when available. The subscripts indicate the number of viruses that were phenotyped. The drug susceptibility assay used was the PhenoSense assay (Monogram, South San Francisco). A hyperlink for each individual pattern is provided to access a complete list of mutations and fold resistances for each sequence matching the pattern of mutation.

A complete summary of additional in vitro susceptibility data for viruses with Q151 obtained using other assays including the Antivirogram can be found here. A complete list of all mutation patterns with Q151 (not just the top 10 most frequent patterns) can be found at this page.

Mutation PatternsNumber of
Sequences
AZT
foldn
D4T
foldn
TDF
foldn
ABC
foldn
DDI
foldn
3TC
foldn
151M1026.795.491.085.296.493.09
151M,184V8312648.140.822131542004
115F,151M,184V5958417.211.612011512001
65R,151M555221423.62111152462
65R,151M,184V31      
65R,70R,151M24      
65R,115F,151M,184V2198512517.51 2211001
115F,151M16      
67N,70R,151M141812.711.613.112.413.51
65R,70R,115F,151M1324001201111201281891
Footnote: Mutation patterns were defined by the presence or absence of major NRTI drug resistance mutations ; Sequences containing a mixture at a major drug resistance positions were excluded; For the cutoffs defined by PhenoSense, open the sample report form provided on this page; The full list of all mutation patterns are also available here.

 

Phenotypic coefficients using machine learning
Least Square Regression (LSR) was used to learn the relative contribution of each mutation to the fold decrease in susceptibility for an ARV. The figure on the left (click to enlarge the figure) shows the regression coefficients (which correlate with the contribution to resistance) for the 23 nonpolymorphic NRTI-resistance mutations shown to contribute decreased susceptibility to at least one NRTI. A complete description of the method that generates this figure can be found at Rhee et al PNAS 2006.